Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
535
datasets available to search
ShareScore release 0.9.0
Dataset results
535 results for “Neovascularization”
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
ClinicalTrials.gov study NCT06742307. IPD Sharing: YES. Countries: 1. Publications: 4.
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
ClinicalTrials.gov study NCT03823287. IPD Sharing: YES. Countries: 15. Publications: 4.
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
ClinicalTrials.gov study NCT05569148. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT02510794. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Data from: Quantifying changes on optical coherence tomography in eyes receiving treatment for neovascular age-related macular degeneration
Open the record for dataset details and reuse information.
Filgrastim, fibrinolysis, and neovascularization
Open the record for dataset details and reuse information.
ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leak
Open the record for dataset details and reuse information.
Quantitative analysis of optical coherence tomography for neovascular age-related macular degeneration using deep learning
<p><strong>Purpose:</strong> To apply a deep learning algorithm for automated, objective, and comprehensive quantification of optical coherence tomography (OCT) scans to a large real-world dataset of eyes with neovascular age-related macular degeneration (AMD), and make the raw segmentation output data openly available for further research.</p> <p><strong>Design:</strong> Retrospective analysis of OCT images from the Moorfields Eye Hospital AMD Database.</p> <p><strong>Participants:</strong> 2473 first-treated eyes and another 493 second-treated eyes that commenced therapy for neovascular AMD between June 2012 and June 2017.</p> <p><strong>Methods:</strong> A deep learning algorithm was used to segment all baseline OCT scans. Volumes were calculated for segmented features such as neurosensory retina (NSR), drusen, intraretinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective material (SHRM), retinal pigment epithelium (RPE), hyperreflective foci (HRF), fibrovascular pigment epithelium detachment(fvPED), and serous PED (sPED). Analyses included comparisons between first and second eyes, by visual acuity (VA) and by race/ethnicity, and correlations between volumes.</p> <p><strong>Main outcome measures:</strong> Volumes of segmented features (mm3), central subfield thickness (CST).</p> <p><strong>Results:</strong> In first-treated eyes, the majority had both IRF and SRF (54.7%). First-treated eyes had greater volumes for all segmented tissues, with the exception of drusen, which was greater in second-treated eyes. In first-treated eyes, older age was associated with lower volumes for RPE, SRF, NSR and sPED; in second-treated eyes, older age was associated with lower volumes of NSR, RPE, sPED, fvPED and SRF. Eyes from black individuals had higher SRF, RPE and serous PED volumes, compared with other ethnic groups. Greater volumes of the vast majority of features were associated with worse VA.</p> <p><strong>Conclusion:</strong> We report the results of large scale automated quantification of a novel range of baseline features in neovascular AMD. Major differences between first and second-treated eyes, with increasing age, and between ethnicities are highlighted. In the coming years, enhanced, automated OCT segmentation may assist personalization of real-world care, and the detection of novel structure-function correlations. These data will be made publicly available for replication and future investigation by the AMD research community.</p>
Data from: Ten-year survival trends of neovascular age-related macular degeneration at first presentation
<p><b>Background:</b> To describe 10-year trends in visual outcomes, anatomical outcomes, and treatment burden of patients receiving anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD).</p> <p><b>Methods: </b>Retrospective cohort study of treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling ≤ 35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA reaching ≥ 70 letters; proportion of eyes with BCVA ≥ 70 and ≤ 35 letters at 10 years; mean trend of BCVA and central retinal thickness (CRT) over 10 years; and mean number of injections.</p> <p><b>Results: </b>For our cohort of 103 patients, Kaplan-Meier analyses demonstrated median time to BCVA reaching ≤35 and ≥70 letters were 37.8 (95% CI 22.2-65.1) and 8.3 (95% CI 4.8-20.9) months after commencing anti-VEGF therapy, respectively. At the final follow-up, BCVA was ≤35 letters and ≥70 letters in 41.1% and 21%, respectively, in first-affected eyes, whilst this was the case for 5.4% and 48.2%, respectively, in a patient's better-seeing eye. Mean injection number was 37.0 ± 24.2 per eye and 53.6 ± 30.1 at patient-level (63.1% of patients required injections in both eyes). </p> <p><b>Conclusions: </b>The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.</p>
Data from: Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD
Purpose: To determine the incidence of new choroidal neovascularization (CNV) in eyes with dry age-related macular degeneration (AMD) following subthreshold diode micropulse laser (SDM). Method: In an observational retrospective cohort study, the records of all patients active in the electronic medical records database were reviewed to identify eyes with dry AMD treated with SDM. Identified eyes were classified by simplified AREDS categories, and analyzed for the primary endpoint of new CNV after treatment. Results: The EMR revealed SDM was offered to 373/392 (95%) patients with dry AMD and elected by 363/373 (97%) between 2008-2017. Follow up was available for 354/363 patients (547 eyes, 98%) (range 6-108 mos., avg. 22). CNV risk factors included age (median 84 years, 67% > 80); reticular pseudodrusen (214 eyes, 39%); AREDS category (78% category 3 and 4); and fellow eye CNV (128 eyes, 23%). New CNV developed in 9/547 eyes (1.6%, annualized rate 0.87%). Visual acuity was unchanged. There were no adverse treatment effects. Summary: In a review of a large group of eyes with exceptionally high-risk AMD, SDM was followed by a very low incidence of new CNV. If confirmed by further study, SDM would offer a new and highly effective treatment to reduce the risk of vision loss from AMD.
Clinical efficacy of conbercept injection on neovascular age-related macular degeneration under different levels of inflammation
<p>Supplementary Tables</p>
The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy
ClinicalTrials.gov study NCT04423406. IPD Sharing: Not stated. Countries: 1. Publications: 1.
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
ClinicalTrials.gov study NCT06198413. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
ClinicalTrials.gov study NCT03930641. IPD Sharing: YES. Countries: 1. Publications: 0.
Bevacizumab for Neovascular Age-related Macular Degeneration
ClinicalTrials.gov study NCT01306591. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Biomarkers and Choroidal Neovascularization
ClinicalTrials.gov study NCT04439708. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
ClinicalTrials.gov study NCT05643118. IPD Sharing: NO. Countries: 1. Publications: 1.
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
ClinicalTrials.gov study NCT04370379. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
ClinicalTrials.gov study NCT03944070. IPD Sharing: NO. Countries: 1. Publications: 2.
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT04537884. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.